Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials

Objective: Whether cardiorenal benefits of liraglutide and semaglutide are consistent across body mass index (BMI) categories is unknown. We performed post hoc analyses on LEADER and SUSTAIN 6 data to evaluate cardiorenal efficacy by BMI groups in patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk. Methods: LEADER and SUSTAIN 6 were randomized CV outcome trials of liraglutide and semaglutide vs placebo in 9340 and 3297 patients, respectively, with T2D and high CV risk. The primary outcome was a composite of CV death, non-fatal myocardial infarction, or non-fatal stroke (major adverse CV events, MACE), with secondary outcomes including nephropathy measures (new or persistent macroalbuminuria, serum creatinine doubling, end-stage kidney disease or death from kidney disease). We evaluated the effect of liraglutide and semaglutide on these cardiorenal outcomes, stratified by baseline BMI groups. Hazard ratios (HRs) for treatment vs placebo were calculated using a Cox proportional hazards mo...